Health News Archive - April 27, 2010
SEATTLE, April 27 /PRNewswire-FirstCall/ -- On Wednesday, April 28, 2010, at 8:30 a.m. Eastern/2:30 p.m. Central European/5:30 a.m.
LONDON, April 27 /PRNewswire/ -- CRESTOR(TM) (rosuvastatin) has been approved in nineteen countries within the EU for the prevention of major cardiovascular events in patients who are at high risk* of having a first cardiovascular event.
PHILADELPHIA, April 27 /PRNewswire/ -- Negotiations broke off early Tuesday morning between Temple University Hospital (TUH) and the Pennsylvania Association of Staff Nurses & Allied Professionals (PASNAP) following a 14-hour session.
MELBOURNE, Australia, April 27 /PRNewswire/ -- Scientists at Australia's Burnet Institute have developed a rapid point-of-care diagnostic test for the measurement of CD4 T-cells, a marker of the immune system for people living with HIV and AIDS.
LONDON, April 27 /PRNewswire/ -- Europe is moving towards becoming a knowledge-based economy. Keeping in line with this objective, the European commission has instituted the Framework 7 (FP7) programme.
ST. LOUIS, April 27 /PRNewswire-FirstCall/ -- Centene Corporation (NYSE: CNC) today announced its financial results for the quarter ended March 31, 2010. The results of operations for our New Jersey health plan, University Health Plans, are classified as discontinued operations.
BEIJING, April 27 /PRNewswire-Asia-FirstCall/ -- Concord Medical Services Holdings Limited ("Concord Medical" or the "Company") (NYSE: CCM), operator of the largest network of radiotherapy and diagnostic imaging centers in China, today announced that its wholly-owned subsidiary, Shenzhen Aohua Medical Device Leasing Co., Ltd., has entered into a definitive agreement to acquire 100% of the equity interest in Tianjin Kangmeng Radiology Equipment Management Co., Ltd.
PARSIPPANY, N.J., April 27 /PRNewswire/ -- To better help meet the needs of smokers who are quitting, Nicorette® launched a mini-sized stop smoking lozenge that dissolves up to three-times faster than other stop smoking lozenges and can double a smoker's chances of successfully quitting versus placebo.
SCHAFFHAUSEN, Switzerland, April 27 /PRNewswire-FirstCall/ -- (Income and EPS amounts are attributable to Tyco common shareholders) ($ millions, except per-share amounts) Q2 2010 Q2 2009 % Change ------- ------- -------- Revenue $4,169 $4,150 - Income/(Loss) from Continuing Operations $310 ($2,555) - Diluted EPS from Continuing Operations $0.65 ($5.40) - Special Items $0.06 ($5.95) Income from Continuing Ops Before Special Items $284 $261 9% Diluted EPS from Continuing Ops Before Special Items $0.59 $0.55 7% Tyco International Ltd.
